A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. I. Clearance

Drug Metabolism and Disposition

Volumn 32, Issue 6, 2004, Pages 603-611

  Ward, Keith W ^a   Smith, Brian R ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

XENOBIOTIC AGENT;

ALLOMETRY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CORRELATION COEFFICIENT; DOG; DRUG CLEARANCE; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; LIVER BLOOD FLOW; MONKEY; NONHUMAN; NORMAL HUMAN; PREDICTION; PRIORITY JOURNAL; RAT; SPECIES DIFFERENCE;

ANIMALS; BIOMETRY; DOGS; DRUG EVALUATION, PRECLINICAL; HUMANS; INJECTIONS, INTRAVENOUS; LIVER CIRCULATION; MACACA FASCICULARIS; MACACA MULATTA; METABOLIC CLEARANCE RATE; PHARMACOKINETICS; RATS; SPECIES SPECIFICITY; XENOBIOTICS;

ANIMALIA; CANIS FAMILIARIS; PRIMATES;

EID: 2442680354     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.32.6.603     Document Type: Article

References (30)

1. Animal Procedures Committee (2002) The Use of Primates under the Animals (Scientific Procedures) Act (1986): Analysis of Current Trends with Particular Reference to Regulatory Toxicology, The Animal Procedures Committee Publications Centre, London, UK.
2. Bonate PL and Howard D (2000) Critique of allometric scaling: does the emperor have clothes? J Clin Pharmacol 40:335-340.
3. Boxenbaum H (1982) Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J Pharmacokinet Biopharm 10:201-227.
4. Boxenbaum H (1984) Interspecies pharmacokinetic scaling and the evolutionary-comparative paradigm. Drug Metab Rev 15:1071-1121.
5. Brazzell RK, Park YH, Wooldridge CB, McCue B, Barker R, Couch R, and York B (1990) Interspecies comparison of the pharmacokinetics of aldose reductase inhibitors. Drug Metab Dispos 18:435-440.
6. Brown RP, Delp MD, Lindstedt SL, Rhomberg LR, and Beliles RP (1997) Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health 13:407-484.
7. Campbell DB (1994) Can allometric interspecies scaling be used to predict human kinetics? Drug Info J 28:235-245.
8. Cherkofsky SC (1995) 1-Aminocyclopropanecarboxylic acid: mouse to man interspecies pharmacokinetic comparisons and allometric relationships. J Pharm Sci 84:1231-1235.
9. Chiou WL and Buehler PW (2002) Comparison of oral absorption and bioavailability of drugs between monkey and human. Pharm Res (NY) 19:868-874.
10. Chiou WL, Jeong HY, Chung SM, and Wu TC (2000) Evaluation of using dog as an animal model to study the fraction of oral dose absorbed of 43 drugs in humans. Pharm Res (NY) 17:135-140.
11. Chiou WL, Robbie G, Chung SM, Wu T-C, and Ma C (1998) Correlation of the plasma clearance of 54 extensively metabolized drugs between humans and rats: mean allometric coefficient of 0.66. Pharm Res (NY) 15:1474-1479.
12. Chiu S-HL, Thompson KA, Vincent SH, Alvaro RF, Huskey S-EW, Stearns RA, and Pettibone DJ (1995) The role of drug metabolism in drug discovery: a case study in the selection of an oxytocin receptor antagonist for development. Toxicol Pathol 23:124-130.
13. Chung M, Radwanski E, Loebenberg D, Lin C-C, Oden E, Symchowicz S, Gural RP, and Miller GH (1985) Interspecies pharmacokinetic scaling of Sch 34343. J Antimicrob Chemother 15 (Suppl C):227-233.
14. Davies B and Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res (NY) 10:1093-1095.
15. Dorato MA and Vodicnik MJ (1994) The toxicologic assessment of pharmaceutical and biotechnology products, in Principles and Methods of Toxicology (Hayes AW ed) pp 189-219, Raven Press, New York, NY.
16. Efthymiopoulos C, Battaglia R, and Strolin Benedetti M (1991) Animal pharmacokinetics and interspecies scaling of FCE 22101, a penem antibiotic. J Antimicrob Chemother 27:517-526.
17. Feng MR, Loo J, and Wright J (1998) Disposition of the antipsychotic, agent CI-1007 in rats, monkeys, dogs and human cytochrome P450 2D6 extensive metabolizers. Drug Metab Dispos 26:982-988.
18. Ings RMJ (1990) Interspecies scaling and comparisons in drug development and toxicokinetics. Xenobiotica 20:1201-1231.
19. Kim SH, Kim WB, and Lee MG (1998) Interspecies pharmacokinetic scaling of a new carbapenem, DA-1131, in mice, rats, rabbits and dogs and prediction of human pharmacokinetics. Biopharm Drug Dispos 19:231-235.
20. Krause W and Kühne G (1993) Pharmacokinetics of rolipram in the rhesus and cynomolgus monkey, the rat and the rabbit. Studies on species differences. Xenobiotica 18:561-571.
21. Kuroda T, Namba K, Torimaru T, Kawashima K, and Hayashi M (2000) Species differences in oral bioavailability of methotrexate between rats and monkeys. Biol Pharm Bull 23:334-338.
22. Mahmood I (1998) Interspecies scaling of renally secreted drugs. Life Sci 63:2365-2371.
23. Mahmood I (1999) Allometric issues in drug development. J Pharm Sci 88:1101-1106.
24. Mahmood I and Balian JD (1996) Interspecies scaling: predicting clearance of drugs in humans. Three different approaches. Xenobiotica 26:887-895.
25. Mahmood I and Sahajwalla C (2002) Interspecies scaling of biliary excreted drugs. J Pharm Sci 91:1908-1914.
26. Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, MacIntyre F, Rance DJ, and Wastall P (1997) The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 283:46-58.
27. Sukbuntherng J, Cropp G, Hannah A, Wagner GS, Shawver LK, and Antonian L (2001) Pharmacokinetics and interspecies scaling of a novel VEGF receptor inhibitor, SU5416. J Pharm Pharmacol 53:1629-1636.
28. Tanaka Y, Sekiguchi M, Sawamoto T, Hata T, Esumi Y, Sugai S, and Ninomiya S (1994) Pharmacokinetics of droloxifene in mice, rats, monkeys, premenopausal and postmenopausal patients. Eur J Drug Metab Pharmacokinet 19:47-58.
29. Ward KW, Proksch JW, Gorycki PD, Yu C-P, Ho MYK, Bush BD, Levy MA, and Smith BR (2002) SB-242235, a selective inhibitor of p38 mitogen-activated protein kinase. II. In vitro and in vivo metabolism and pharmacokinetic extrapolation to man. Xenobiotica 32:235-250.
30. Ward KW, Azzarano LM, Bondinell WE, Cousins RD, Huffman WF, Jakas DR, Keenan RM, Ku TW, Lundberg D, Miller WH, et al. (1999) Preclinical pharmacokinetics of a novel vitronectin receptor antagonist. Drug Metab Dispos 27:1232-1241.